Xeris Biopharma (XERS) Set to Announce Quarterly Earnings on Friday

Xeris Biopharma (NASDAQ:XERS) is scheduled to be announcing its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. During the same quarter in the prior year, the business posted ($0.14) EPS. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Stock Up 2.5 %

Shares of XERS stock opened at $3.34 on Thursday. The stock has a market cap of $497.66 million, a P/E ratio of -7.58 and a beta of 2.70. Xeris Biopharma has a 52 week low of $1.46 and a 52 week high of $3.39. The company’s fifty day simple moving average is $2.93 and its two-hundred day simple moving average is $2.47.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Xeris Biopharma in a research note on Thursday, August 15th.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.